HEALTH TECHNOLOGY

NUTEX HEALTH ANNOUNCES TWO NEW FULLY FUNCTIONAL MICRO HOSPITALS

Nutex Health, Inc. | May 17, 2022

NUTEX HEALTH

Nutex Health Inc. a physician-led, technology-enabled healthcare services company comprised of a hospital division with 21 facilities in 8 states and a primary care-centric, risk-bearing population health management division, announced two new fully operational micro hospitals.

The first hospital, New Braunfels ER & Hospital, is in New Braunfels, Texas, located about 30 miles northeast of San Antonio.  The state-of-the-art facility is open 24/7, 365 days a year, and includes an emergency room with 9 private exam rooms staffed with board-certified physicians and 4 private inpatient beds.  The hospital provides both adult and pediatric care, and has the most advanced imaging and laboratory equipment, including CT, X-Ray and ultrasound with rapid radiological reports.

The second hospital, East Valley ER & Hospital, is in Gilbert, Arizona, located about 21 miles southeast of Phoenix. The state-of-the-art hospital is open 24/7, 365 days a year, and includes an emergency room with 14 private exam rooms and 14 private inpatient beds. The hospital provides both adult and pediatric care, and has the most advanced imaging and laboratory equipment, including MRI, CT, X-Ray and ultrasound.

Nutex currently anticipates opening 3 more facilities in 2022, with another 17 facilities either under construction or in advanced planning stages and anticipated to open in 2023 and 2024.  There can be no assurance that these additional facilities will open in the anticipated timing or that they will open at all.

Nutex micro hospitals focus on ensuring that patients receive a premium patient experience.  Our hospitals feature short ER wait times averaging 15 minutes from entering the door to seeing a physician, high-quality care, lower nursing- and physician-to-patient staffing ratios and faster discharge times.  Physicians, nurses and other employees are incentivized to provide quality, compassionate care to their patients.  Nutex micro hospitals consistently have better outcomes and high patient satisfaction scores, with well over 1000 five-star Google reviews.

"We are excited to continue to expand Nutex's network of micro hospitals across the country. Both New Braunfels and Gilbert are vibrant and rapidly growing suburbs of major metropolitan areas.  Our goal is to provide high-quality acute medical care to the populations of these communities."

Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health

 

"Entering the medical field, my goal was always to try to revolutionize the way healthcare is delivered to our patients.  Our unique model allows physicians and nurses to retake control of patient care," stated Trey Allen, M.D., Medical Director at New Braunfels ER & Hospital.  "We are committed to working with the community to make sure they can receive the healthcare they deserve."

"As physicians, we saw how healthcare was being delivered, and we felt we could do better.  We felt the humanity and compassion were absent from many medical interactions.  We value and respect our patients, and treat them as family," stated Daniel Stites, M.D., Medical Director at East Valley ER & Hospital.

About Nutex Health Inc.

Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. is a physician-led, technology-enabled healthcare services company with approximately 1500 employees nationwide and is partnered with over 800 physicians. The Company has two divisions a Hospital division and a Population Health Management division. The hospital division owns and operates 21 facilities in eight different states.  The division implements and operates different innovative health care models, including micro hospitals, specialty hospitals and hospital outpatient departments. The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organizations, we provide management, administrative and other support services to our affiliated hospitals and physician groups. Our cloud-based proprietary technology platform aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers, allowing us to deliver greater quality care more efficiently. 

Safe Harbor

Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Federal Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will", "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company.  Such uncertainties and risks include the ability to realize the anticipated benefits of the transaction, significant transaction costs and unknown liabilities and litigation and regulatory risks related to the transaction.   In addition, forward-looking statements are subject to additional uncertainties and risks facing the Company, including but not limited to, economic conditions, dependence on management, dilution to stockholders, lack of capital, changes in laws or regulations, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's  ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

Spotlight

Americans are more focused than ever on the rising out-of-pocket cost of health care, both in terms of personal finances and the national economy.

Spotlight

Americans are more focused than ever on the rising out-of-pocket cost of health care, both in terms of personal finances and the national economy.

Related News

FUTURE OF HEALTHCARE

Veradigm Digital Health Media Becomes the First EHR Marketing Solution to Join the Point of Care Marketing Association

Veradigm | November 23, 2022

Veradigm, a business unit of Allscripts announced The Point of Care Marketing Association a nonprofit organization to support the continued growth of the Point of Care channel through education and advocacy, has welcomed Veradigm to its membership. Veradigm Digital Health Media is the first EHR marketing solution to be accepted as a member of POCMA Stuart Green, Senior Vice President & General Manager, Veradigm has joined POCMA’s board of directors POCMA exists to advocate for the effective use of the point of care communication channel to advance patient healthcare outcomes. Members of the nonprofit point of care industry association work closely with brand, agency, and provider stakeholders to advocate for the channel and promote its positive impact to ensure its continued growth as a vital and innovative segment of healthcare marketing. “POCMA is excited to have Veradigm as a member and the first within the EHR landscape. Veradigm’s platform of reaching HCPs in their workflow makes them an excellent resource for the association and its members. We look forward to their insights and involvement as we grow the POC industry.” POCMA Executive Director, Nicole Divinagracia “At Veradigm, we share in POCMA’s goal of raising healthcare providers’ awareness through innovative point of care marketing channels,” said Stuart Green, Senior Vice President & General Manager, Veradigm. “With our membership, we look forward to contributing to the establishment of industry best practices and building connections with other point-of-care industry leaders and influencers.” About Allscripts Allscripts is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. About Veradigm® Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. Some healthcare technology companies deliver clinical data for biopharma and health plans, some help turn that data into insights, others serve healthcare providers directly by providing point-of-care clinical software and patient outreach platforms. Veradigm does it all. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions, all working together to transform healthcare insightfully.

Read More

HEALTH TECHNOLOGY, DIGITAL HEALTHCARE

Masimo and Philips Introduce Masimo W1 Watch As Part of a Global Partnership

Masimo | January 19, 2023

On January 18, 2023, Masimo and Royal Philips announced an extension of their partnership to expand the capabilities for patient monitoring in home telehealth applications. Masimo W1™ advanced health tracking watch will unite with Philips' enterprise patient monitoring ecosystem, advancing telemonitoring and telehealth. Masimo W1 is the first wristwatch to provide continuous, precise pulse oximetry measures and other health-related information. Masimo's secure health data cloud will transmit patient information to Philips' patient monitoring environment thereby, facilitating remote clinician monitoring. Hospital experts will remotely monitor patients' vital signs while they go about their regular lives. Physicians can confidently discharge patients, knowing that Masimo W1 will monitor their vital signs while Philips dashboards will scrutinize their physiological status. It will enable physicians and nurses to detect a patient's deterioration earlier and provide better care. This innovative combination of monitoring and networking technology will offer numerous opportunities, including early discharge initiatives, hospital-at-home programs, and the management of chronic illness. Bilal Muhsin, Chief Operating Officer of Masimo Healthcare, expressed, "Expanding our partnership with Philips in this way is a win-win for patients and clinicians everywhere, and is an important part of our multi-year plan to bring the best of hospital monitoring to the home while continuing to improve access to quality hospital care." (Source – Business Wire) About Masimo Masimo develops and manufactures innovative, non-invasive patient monitoring technologies, including medical devices and sensors. The company is making a measurable difference in the world by saving, extending, and improving the lives of people of all ages. For over 30 years, its innovative medical technologies and non-invasive patient monitoring solutions have solved 'unsolvable' problems. The result is a portfolio of clinically-proven products that lead the way in innovation, performance, and patient safety by giving healthcare providers the information they need to optimize clinical decision-making. Through the Masimo Hospital AutomationTM platform, Masimo connectivity, automation, and telehealth and telemonitoring solutions are improving and automating care delivery both in and out of the hospital.

Read More

FUTURE OF HEALTHCARE

Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease

Anumana | December 16, 2022

Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has entered into a multi-year agreement with Pfizer, Inc. for Anumana to develop an artificial intelligence electrocardiogram algorithm designed to enable the early suspicion of cardiac amyloidosis. Anumana will conduct a clinical validation trial and pursue De Novo classification for the algorithm as a Software-as-a-Medical-Device and aims to gain regulatory approval for the algorithm as an SaMD for the detection of cardiac amyloidosis in the U.S., Europe and Japan. Cardiac amyloidosis is a serious, progressive, and underdiagnosed rare disease that leads to heart failure.1 In patients with cardiac amyloidosis, the heart walls become stiff, making it difficult for the left ventricle to properly relax and fill with blood, while at the same time hampering its ability to squeeze and pump blood out of the heart. Symptoms and comorbidities associated with cardiac amyloidosis, such as shortness of breath, knee pain, bilateral carpal tunnel syndrome, kidney disease, and gastrointestinal issues, can vary and seem unrelated, making diagnosis difficult.2,3 “The challenge in diagnosing cardiac amyloidosis can prevent patients from getting treatment while the disease continues to progress. We believe this collaboration will demonstrate the power of Anumana’s AI-ECG algorithms to help clinicians intervene earlier, giving them greater ability to improve patient outcomes and prolong lives.” David McMullin, chief business officer of Anumana The research agreement with Pfizer will help deepen Anumana’s efforts to implement AI-enabled early detection software that can reveal signals from ECGs that humans cannot interpret. The ubiquitous nature of the painless, non-invasive 100-year-old ECG test gives AI-ECG algorithms the potential to reach a larger number of patients earlier. “AI-ECG solutions alert clinicians to humanly imperceptible patterns in ECG signals, providing an early warning for serious occult or impending disease,” said Paul Friedman, M.D., Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Chair of Anumana’s Mayo Clinic Board of Advisors. “This stands to improve the lives of people with cardiac amyloidosis by improving the speed of triage and care of this group.” Anumana was founded in 2021 in collaboration with the Mayo Clinic Platform. Anumana has licensed Mayo Clinic AI-ECG algorithms for low ejection fraction, pulmonary hypertension, and hyperkalemia, all of which have received Breakthrough Device Designation from the U.S. FDA. These algorithms have been validated by over 75 peer-reviewed publications, including a first of its kind prospective clinical impact study on low ventricular ejection fraction that was published in Nature Medicine in 2021, and another first of its kind batch enrolled prospective clinical impact study that demonstrated the effectiveness of AI-ECG to screen for undetected atrial fibrillation in normal sinus rhythm that was published in The Lancet in 2022. About Anumana Anumana, an AI-driven health technology company and portfolio company of nference, is harnessing industry-leading AI and translational science to unlock the electrical language of the heart as never before. Anumana algorithms have been developed, trained, and validated using clinical data from Mayo Clinic and other leading institutions to detect hidden diseases using AI-ECG algorithms and to enhance and improve interventional procedures through real-time AI techniques. Multiple Anumana algorithms have received FDA Breakthrough Device Designation and are currently undergoing rigorous clinical trial validation. Anumana software devices are designed for real-world physician use, integrating into existing workflows at the point of care to reduce costs and enhance quality of life. Anumana algorithms are investigational medical devices and have not yet received regulatory approval or clearance.

Read More